Monument Therapeutics Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis 10 Mar Written By Alexandra Collingbourne Alexandra Collingbourne
Monument Therapeutics Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis 10 Mar Written By Alexandra Collingbourne Alexandra Collingbourne
